The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | PILOT study – patient characteristics and key results
Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, briefly discusses the patient population enrolled in the PILOT study (NCT03483103), which is evaluating the safety and efficacy of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Although all patients in this study presented with high-risk disease features, treatment with liso-cel demonstrated a high overall response rate (ORR) and manageable toxicity profile. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche
